News-Medical.netOcular oncologists link immunotherapy with potentially vision-robbing side effectNews-Medical.netNew immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bl… Continue reading
FDA Greenlights CAR T Therapy for Large B-Cell LymphomaSpecialty Pharmacy TimesOfficials with the FDA have expanded the approval for the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah, Novartis) for the treatment of adult pati… Continue reading
FDA Greenlights CAR T Therapy for Large B-Cell LymphomaSpecialty Pharmacy TimesOfficials with the FDA have expanded the approval for the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah, Novartis) for the treatment of adult pati… Continue reading
|
Immunotherapy in GU Cancers: Combinations Are the Next Step
Curetoday.com “In bladder cancer and kidney cancer in particular, we’re seeing a wave of new therapies, such as how to use novel immunotherapies effectively. There are trials now that are addressing combination approaches that I believe will quickly lead to new … |
UCalgary News |
Researchers clarify the identity of brain stem cells
EurekAlert (press release) Unfortunately, when brain cells are damaged by trauma or disease they don’t automatically regenerate. This can lead to permanent disability. But within the brain there are a small number of stem cells that persist into adulthood, offering a possible … Researchers clarify the identity of adult brain stem cellsUCalgary News |
FierceBiotech |
Sarepta adds muscular dystrophy gene therapies via Myonexus pact
FierceBiotech Sarepta is determined to stay at the forefront of genetic medicines for muscular dystrophies and to that end has signed another R&D deal—this time with Myonexus Therapeutics—and taken an option on buying the company. The $60 million upfront deal … Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene …GlobeNewswire (press release) Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drugEndpoints News |
|
Synthetic Biology Market Till 2024 Research Report | DecisionDatabases
Expert Consulting Synthetic Biology Market Report added by DecisionDatabases.com offers industry size, share, growth, trends and forecast analysis upto 2024. Synthetic Biology Market Report also covers top key players, porter’s five forces analysis and market … |